 Tetrahydroisoquinolines
"Tetrahydroisoquinolines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of ISOQUINOLINES in which the nitrogen containing ring is protonated. They derive from the non-enzymatic Pictet-Spengler condensation of CATECHOLAMINES with ALDEHYDES.
| Descriptor ID |
D044005
|
| MeSH Number(s) |
D03.633.100.531.820
|
| Concept/Terms |
Tetrahydroisoquinolines- Tetrahydroisoquinolines
- Tetrahydro-Isoquinolines
- Tetrahydro Isoquinolines
- 1,2,3,4-Tetrahydroisoquinolines
|
Below are MeSH descriptors whose meaning is more general than "Tetrahydroisoquinolines".
Below are MeSH descriptors whose meaning is more specific than "Tetrahydroisoquinolines".
This graph shows the total number of publications written about "Tetrahydroisoquinolines" by people in this website by year, and whether "Tetrahydroisoquinolines" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 0 | 1 | | 2004 | 1 | 0 | 1 | | 2007 | 1 | 0 | 1 | | 2008 | 0 | 1 | 1 | | 2011 | 0 | 1 | 1 | | 2014 | 1 | 0 | 1 | | 2015 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Tetrahydroisoquinolines" by people in Profiles.
-
Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, Milhem M, Elias A, Ganjoo K, Tawbi H, Van Tine BA, Spira A, Dean A, Khokhar NZ, Park YC, Knoblauch RE, Parekh TV, Maki RG, Patel SR. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. J Clin Oncol. 2016 Mar 10; 34(8):786-93.
-
Lopez JP, Gajdos C, Elias A. Trabectedin: novel insights in the treatment of advanced sarcoma. Curr Oncol Rep. 2014 Jun; 16(6):387.
-
Gore L, Rivera E, Basche M, Moulder-Thompson SL, Li J, Eppers S, Grolnic S, O'Bryant C, Cleere D, Elsayed YA, Eckhardt SG. Phase I combination study of trabectedin and capecitabine in patients with advanced malignancies. Invest New Drugs. 2012 Oct; 30(5):1942-9.
-
Messersmith WA, Jimeno A, Ettinger D, Laheru D, Brahmer J, Lansey D, Khan Y, Donehower RC, Elsayed Y, Zannikos P, Hidalgo M. Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2008 Dec; 63(1):181-8.
-
Roylance R, Seddon B, McTiernan A, Sykes K, Daniels S, Whelan J. Experience of the use of trabectedin (ET-743, Yondelis) in 21 patients with pre-treated advanced sarcoma from a single centre. Clin Oncol (R Coll Radiol). 2007 Oct; 19(8):572-6.
-
Sauer WH, Baer JT, Berlin JA, Kimmel SE. Class effect of angiotensin-converting enzyme inhibitors on prevention of myocardial infarction. Am J Cardiol. 2004 Nov 01; 94(9):1171-3.
-
Carroll I, Thomas JB, Dykstra LA, Granger AL, Allen RM, Howard JL, Pollard GT, Aceto MD, Harris LS. Pharmacological properties of JDTic: a novel kappa-opioid receptor antagonist. Eur J Pharmacol. 2004 Oct 06; 501(1-3):111-9.
-
Blumer JL, Daniels SR, Dreyer WJ, Batisky D, Walson PD, Roman D, Ouellet D. Pharmacokinetics of quinapril in children: assessment during substitution for chronic angiotensin-converting enzyme inhibitor treatment. J Clin Pharmacol. 2003 Feb; 43(2):128-32.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|